Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
Cet article analyse les limites de la charge mutationnelle tumorale pour prédire les résultats d'une immunothérapie chez les patients atteints d'un cancer puis examine les stratégies potentielles pour optimiser l'utilisation clinique de ce biomarqueur
Tumor mutational burden (TMB) is a biomarker that measures the number of somatic mutations in a tumor's genome. TMB has emerged as a predictor of response to immune checkpoint inhibitors (ICIs) in various cancer types, and several studies have shown that patients with high TMB have better outcomes when treated with PD-(L)1-based therapies. Recently, the FDA has approved TMB as a companion diagnostic for the use of pembrolizumab in solid tumors. However, despite its potential, the use of TMB as a biomarker for immunotherapy efficacy is limited by several factors. Here we review the limitations of TMB in predicting immunotherapy outcomes in patients with cancer and discuss potential strategies to optimize its use in the clinic.
Annals of Oncology , résumé, 2023